Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Apr 04, 2017 10:18am
191 Views
Post# 26072647

RE:Regular Asperin Use

RE:Regular Asperin UseG1945,

First of all, you cite an article focused on aspirin and cancer mortality, and not aspirin and CVD. Does aspirin offer protection against cardiac events in high-risk patients? The American Heart Association, the American Stroke Association and the American Diabetes Association recommend the use of low-dose aspirin for prevention of cardiovascular disease in adults whose risk is sufficiently high for the benefits to outweigh the risks associated with treatment (e.g. bleeding). They suggest that a 10-year CVD risk of 6% to 10% is sufficient. 

Aspirin is not a new drug and has likely been recommended to high-risk CVD patients for many years now even before launch of BETonMACE. I wouldn't be surprised if many of the physicians are already recommended patients enrolled in BETonMACE to take aspirin. Keep in mind that this is a randomized trial. Therefore, both placebo group (statin only) and RVX-208 group (statin plus RVX-208) would both potentially be recommended to take aspirin. So there shouldn't be any worry of aspirin use affecting BETonMACE in my opinion. Furthermore, if RVX-208 does what we all think and hope that it does, then the cardiovascular protection offered by RVX-208 is goign to far outweigh the protection offered by statins/aspirin alone.

BearDownAZ
Bullboard Posts